On June 26, 2025, Erik Darius Mardiwidyo, Chairman of Indonesian pharmaceutical firm Mepro (3-person delegation), and Gelani Azirov, President of Russian company Escom (6-person delegation), visited Yangtze River Pharmaceutical Group to explore cooperation opportunities in the pharmaceutical market. Tan Guangzhao, Head of the Group's Production System, Zheng Shaobo, Assistant Director of Jiangsu Haici Biological Pharmacy, Shen Peng, Director of the International Business Center of the Production Operations Department, and other leaders received and engaged in discussions with the delegations.
A delegation led by the Chairman of Mepro Pharmaceuticals visited Yangtze River Pharmaceutical Group. At Longfengtang Factory, the TCM production base, they toured the solid preparation, extraction workshops and specimen hall, learning about TCM production and cultural heritage. Impressed by the modern TCM production system, Mepro expressed interest in future cooperation. At the headquarters, they visited Lyophilized Powder Injection Workshop No.3 and Large-Volume Injection Workshop No.4, praising the advanced processes, smart management and quality systems. They hailed Yangtze River Pharmaceutical Group as the largest they'd inspected, noting its valuable practices.
The two sides exchanged in-depth views on corporate development and strategic planning, jointly defining the future cooperation direction. In response to Mepro's specific needs in TCM factory planning, supply chain collaboration, technology transfer, and product expansion, we provided positive feedback on each item. We also shared our TCM market promotion and marketing strategies. The Mepro team expressed gratitude and looks forward to broader cooperation in the TCM field.
During their visit to Yangtze River Pharmaceutical Group, Escom's delegation led by its President toured Utility Workshop No.3, Large-Volume Injection Workshop No.4 and Lyophilized Powder Injection Workshop No.2. They praised the advanced production processes, intelligent management and standardized quality control, noting their reference value in production and technology, especially the modern management of the two formulation workshops. The delegation later visited Haici Biological's General Drug Raw Material Workshop No.5. Both sides discussed cooperation details, confirmed the first batch of API projects, and Escom expressed intent to deepen API cooperation.
The two sides exchanged overviews and development plans, discussing operational challenges and key concerns to define future cooperation directions. Regarding the need to establish an API plant, they held in-depth technical talks on a sodium chloride API workshop. Facing issues like single product variety and low profits, both sides communicated on dosage form expansion and raw material supply needs, reaching intent for further cooperation after thorough discussions.
Against the backdrop of the Belt and Road Initiative and Sino-Indonesian/Sino-Russian community with a shared future, the two sides are charting a new pharmaceutical cooperation blueprint under the principles of mutual benefit, win-win results and complementary advantages. Yangtze River Pharmaceutical Group will deepen its global strategic footprint, partner with world-class enterprises, and jointly drive the high-quality development of the regional pharmaceutical industry.
